N Rcus Us03969f1093 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

– Clinically Meaningful Reduction in Risk of Progression or Death Was Observed in the Domvanalimab-Containing Study Arms Compared to Zimberelimab Monotherapy in First-Line, PD-L1-High NSCLC. | June 3, 2023

Foster cityUnited statesDimitry sa nuytenMelissal johnsonExchange commissionArcus biosciences incGilead sciencesSarah cannon research instituteLung cancer researchGilead sciences incArcus biosciencesRapid abstract updatesLead investigatorFree survivalResponse rateChief medical officer